BHVN - Biohaven Pharmaceutical Holding Company Ltd.
| Previous Close | 45.30 |
| Open | 45.10 |
| Bid | 45.36 x 1200 |
| Ask | 45.50 x 800 |
| Day's Range | 44.46 - 45.84 |
| 52 Week Range | 29.17 - 67.86 |
| Volume | 197,027 |
| Avg. Volume | 1,021,577 |
| Market Cap | 2.345B |
| Beta (3Y Monthly) | 0.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.30 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 77.22 |
- Yahoo Finance Video•2 days ago
Biohaven reveals positive results in migrane drug trial
Biohaven Pharmaceuticals, which recently announced a positive Stage 3 trial for one of its migraine treatments. Dr. Vlad Coric, CEO of Biohaven, discusses the future of the drug and the company with Yahoo Finance's Alexis Christoforous and Brian Sozzi
- PR Newswire•2 days ago
Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet
NEW HAVEN, Conn., July 15, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announces that The Lancet published online positive results from a Phase 3 pivotal clinical trial of rimegepant Zydis® orally dissolving tablet (ODT) for the acute treatment of migraine.
- PR Newswire•6 days ago
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
- Rimegepant Zydis® Oral Fast-Dissolve Tablet (ODT) Phase 3 results demonstrate rapid and sustained benefits for the acute treatment of migraine - Presentations also include: -New interim analyses from ...
- PR Newswire•6 days ago
Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
-Research suggests patients define effective migraine therapies as reliable pain relief that enables them to return to their lives. Current treatments limit the ability for some patients to reach their treatment goals due to nonresponse to standard therapies and side effects. NEW HAVEN, Conn., July 11, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), has launched a campaign called 'Demand More' highlighting what patients want and need from an acute treatment of migraine in their own words.
- Benzinga•6 days ago
The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 10) CONMED Corporation (NASDAQ: CNMD ) Eidos Therapeutics ...
- PR Newswire•7 days ago
Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine
NEW HAVEN, Conn., July 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), announced today that positive results from a Phase 3 pivotal clinical trial of rimegepant, Biohaven's small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine, are published in the July 12, 2019 issue of the New England Journal of Medicine (NEJM).
- TheStreet.com•7 days ago
2 Single Hitters That Could Score With the 'Write' Strategy
The contest was won by rookie Peter Alonso -- about the only good thing about the Mets season to this point. The stock fell some 30% in short order after announcing and executing a $300 million secondary offering to raise funding.
- GuruFocus.com•12 days ago
Biohaven Offering Seems to Make Sale Less Likely
Company among 4 small cap pharma firms listed as takeover targets
- PR Newswire•16 days ago
Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia
Trigeminal neuralgia is a neuropathic pain disorder characterized by recurrent, paroxysmal, lancinating pain in the distribution of one or more branches of the trigeminal nerve. These episodic bouts of severe facial pain can last seconds to minutes, occur several times per day, and often result in significant disability. The neuropeptide calcitonin gene-related peptide (CGRP) is thought to play an important role in the development of neuronal sensitization and neuropathic pain and its aberrant release from the trigeminal nerve has been implicated in the pathophysiology of trigeminal neuralgia.
- GuruFocus.com•20 days ago
Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Bought $201,100 of Shares
CEO of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Vlad Coric bought 5,000 shares of BHVN on 06/26/2019 at an average price of $40.22 a share.
- PR Newswire•23 days ago
Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist
-Rimegepant leads the meeting with the most presentations for an oral small molecule CGRP receptor antagonist, including 14 late breakers -Oral Presentation of rimegepant Zydis® Orally Dissolving Tablet ...
- PR Newswire•28 days ago
Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares
NEW HAVEN, Conn. , June 18, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product ...
- Bloomberg•29 days ago
Migraine-Drug Deal Hype Turns Into a Giant Headache
(Bloomberg Opinion) -- Biohaven Pharmaceutical Holding Co. has rapidly transformed from one of biotech’s darlings into a cautionary tale of overheated M&A hype. Shares of the developer of migraine treatments surged in April after Bloomberg News reported that the company was considering a sale; the stock then took another leg up earlier this month when Biohaven canceled plans to attend a Goldman Sachs health-care conference, fueling speculation a takeover was imminent. All those gains evaporated this week when the company instead announced that it was selling more shares, something that wouldn’t happen if a deal was in sight. As of midday Tuesday, the stock was down 35 percent from its highs: Biohaven’s ongoing single status shouldn’t have come as so much of a shock. The company has arguably never been as compelling an M&A target as some investors and analysts seem to think, and faces significant risks if it has to go it alone. Deal hype isn’t a self-fulfilling prophecy in biotech; in fact, it can sometimes backfire and result in the exact opposite. In the case of Biohaven, the company’s lead drug in development is a migraine pill that takes the same approach as a group of three recently approved injectable medicines that can help prevent the debilitating headaches. Biohaven's drug is a fast-acting alternative, but it will have to compete for a subset of the market with cheaper generic options and a direct rival from Allergan PLC.The drug’s tough path forward is one of the reasons Biohaven was likely open to a buyout; this launch will be even harder and slower without the financial resources and commercial expertise of a larger company. But that same dynamic is also potentially what’s keeping potential suitors away. Biohaven just isn’t the sort of company that pharma has been buying. The sweet spot of M&A in the industry has centered around cancer drugs and rare-disease treatments that command very high prices, partly by sidestepping the pricing and reimbursement problems that dog larger and more competitive markets such as the one for migraine remedies. Most recent biopharma acquisitions above $1.5 billion have been for companies working in these areas or for drugs that already generate sales. It’s possible that a drugmaker could decide to do something different, but it would need a compelling reason, and the hype-driven ascent of BioHaven’s valuation doesn’t help.This is pretty clearly a situation where takeover excitement got well ahead of reality, which isn’t uncommon in biotech. But context matters, and any investment thesis that depends on big pharma expensively bucking an M&A trend to get itself into a possible price war deserves some extra skepticism.To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
- Motley Fool•29 days ago
Here's Why Biohaven Pharmaceutical Plummeted Today
Dilution is coming for shareholders, while an acquisition doesn't seem as likely.
- Benzinga•29 days ago
The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
- Simply Wall St.•29 days ago
Should Biohaven Pharmaceutical Holding (NYSE:BHVN) Be Disappointed With Their 36% Profit?
The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...
- PR Newswire•last month
Biohaven Announces Proposed Public Offering Of Common Shares
NEW HAVEN, Conn., June 17, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting neurological diseases, including rare disorders, today announced that it has commenced an underwritten public offering of $300 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of common shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
- Investor's Business Daily•last month
Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
- Insider Monkey•last month
Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]
- Zacks•last month
Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock
Biohaven Pharmaceutical (BHVN) needs investors to pay close attention to the stock based on moves in the options market lately.
- PR Newswire•2 months ago
Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP-Targeting Monoclonal Antibodies
- Over 105,000 doses of rimegepant 75 mg have been administered in over 1,780 migraine patients in the long-term safety study to date - Safety profile remains favorable with no liver safety signal detected ...
- PR Newswire•2 months ago
Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms
- Phase 2/3 clinical trials of troriluzole, a glutamate modulator, in Alzheimer's disease, generalized anxiety disorder, and obsessive-compulsive disorder are all expected to complete enrollment by end ...
- PR Newswire•2 months ago
Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
- Secured Priority Review Voucher (PRV) enabling expedited regulatory review of rimegepant Zydis® ODT New Drug Application (NDA) - Completed $125 million preferred stock sale to Royalty Pharma - Continued ...
- PR Newswire•2 months ago
Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event
- Late-Breaking oral presentation accepted at AAN: First public disclosure of the complete rimegepant Zydis® oral fast-dissolve tablet (ODT) Phase 3 clinical trial results showing single-dose, rapid and ...
